To subscribe:
To have your comment included in a future podcast, call 617-440-4374. Please leave your name, number, and the podcast ID number.
(2 votes, average: 3.50 out of 5)This week, a conversation with Michael Hochman on his examination of what the major general journals publish in the way of comparative effectiveness studies. He talks about what they are and how to think about that reprint that the drug rep has just dropped off for you.
Reach us at 617-440-4374, or write to jelia@jwatch.org.
This week’s [...]
(1 votes, average: 3.00 out of 5)Our attempts to get an interview with a researcher were unavailing, so we’ve gone to plan B and repeat a useful look at treating community-acquired pneumonia according to guideline recommendations.
Please leave comments and complaints at jelia@jwatch.org. You can call and voice these at 1-617-440-4374.
Interview-related links:
Community-Acquired Pneumonia: Guideline-Compliant Treatment Is Better
IDSA/ATS guidelines
News-related links:
Evaluating long-term risk via [...]
(2 votes, average: 5.00 out of 5)A conversation with the authors of an Archives of Internal Medicine study that examines the best tactics for saying “No” to inappropriate requests.
Contact me at 1-617-440-4374 or at jelia@jwatch.org.
Interview-related links:
Archives of Internal Medicine abstract
Atul Gawande’s New Yorker article
News-related links:
The rosiglitazone (Avandia) controversy
Advisory on thiazolidinediones
Physicians’ work hours
13-valent pneumococcal vaccine
Influenza-vaccination expansion
Group CBT for low-back pain
(2 votes, average: 5.00 out of 5)Patients with hypertension at risk for cardiovascular events have done better with an ACE inhibitor-calcium channel blocker combination than with the ACE inhibitor plus hydrochlorothiazide. The ACCOMPLISH investigators have now reported on their analysis of progression-of-nephropathy outcomes in their trial. We interview the first author of the analysis, Dr. George Bakris of the University of [...]
(6 votes, average: 3.33 out of 5)We talk with Dr. Catherine Kelly about her study in BMJ showing serious interference of some SSRIs with tamoxifen therapy in breast cancer. The study was conducted using Canadian provincial databases.
Reach us at 1-617-440-4374 or by email to jelia@jwatch.org.
Interview article:
BMJ study
Physician’s First Watch coverage
Medical news links:
Back pain guidelines
Inflammatory bowel disease and venous thromboembolism
Automated calling systems
Journal Watch — Recent Gastroenterology Articles Journal Watch — Recent General Medicine Articles Journal Watch — Recent Infectious Disease Articles
